These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10453433)

  • 21. Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns.
    Ruof J; Klein G; März W; Wollschläger H; Neiss A; Wehling M
    Prev Med; 2002 Jul; 35(1):48-53. PubMed ID: 12079440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized controlled trial of a physician-directed treatment program for low-income patients with high blood cholesterol: the Southeast Cholesterol Project.
    Keyserling TC; Ammerman AS; Davis CE; Mok MC; Garrett J; Simpson R
    Arch Fam Med; 1997; 6(2):135-45. PubMed ID: 9075448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
    Schectman G; Hiatt J
    Am J Med; 1996 Feb; 100(2):197-204. PubMed ID: 8629655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease.
    Harnick DJ; Cohen JL; Schechter CB; Fuster V; Smith DA
    Am J Cardiol; 1998 Jun; 81(12):1416-20. PubMed ID: 9645890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study.
    Diamantopoulos EJ; Athyros VG; Yfanti GK; Migdalis EN; Elisaf M; Vardas PE; Manolis AS; Karamitsos DT; Ganotakis ES; Hatseras D;
    Angiology; 2005; 56(6):731-41. PubMed ID: 16327950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
    Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
    Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW; Schultz JS; O'Donnell JC; Patel PA; Sasane RM
    Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events.
    Ito MK; Delucca GM; Aldridge MA
    J Cardiovasc Pharmacol Ther; 2001 Apr; 6(2):129-35. PubMed ID: 11509919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive cardiac rehabilitation improves the control of dyslipidemia in secondary prevention.
    Vergès BL; Patois-Vergès B; Cohen M; Casillas JM
    J Cardiopulm Rehabil; 1998; 18(6):408-15. PubMed ID: 9857272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The undertreatment of LDL-cholesterol: addressing the challenge.
    Pearson TA
    Int J Cardiol; 2000 Jun; 74 Suppl 1():S23-8. PubMed ID: 10856770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?
    Jones PH
    Drugs; 2000 May; 59(5):1127-35. PubMed ID: 10852644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.
    Stefanutti C; Morozzi C; Di Giacomo S
    Curr Med Chem; 2012; 19(28):4861-8. PubMed ID: 22963620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achieving cholesterol target in a managed care organization (ACTION) trial.
    Straka RJ; Taheri R; Cooper SL; Smith JC
    Pharmacotherapy; 2005 Mar; 25(3):360-71. PubMed ID: 15843283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors predicting improvements in lipid values following cardiac rehabilitation and exercise training.
    Lavie CJ; Milani RV
    Arch Intern Med; 1993 Apr; 153(8):982-8. PubMed ID: 8481069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP).
    Ito MK; Stolley SN; Morreale AP; Lin JC; Marcus DB
    Am J Health Syst Pharm; 1999 Jun; 56(11):1107-13. PubMed ID: 10385458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The surveillance of cholesterol management in the cardiac rehabilitation setting.
    Wyman R; Vitcenda M; McBride P
    J Cardiopulm Rehabil; 2002; 22(4):245-50. PubMed ID: 12202843
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.